CRIZOTINIB CNS resistance
Ceritinib
Alectinib
Brigatinib
Trial
ASCEND-1
(All)
ASCEND-2
(measurable, active)
Measurable
*
Non measurable
*
Phase I/II
(measurable)
Phase I/II
(Non measurable)
ALTA
(measurable)
180 mg
ALTA
(All)
180m
g
N
75
20
50
136
15
31
18
72
RR
19
45
64
42.6
67
42
67
31
CRR
5
10
22
27.2
7
42
0
14
DCR
65
80
90
85.3
87
94
83
86
PFS
6
-
-
-
15.6
NR
NR
Ou SH-I, et al. WCLC 2016; Gettinger S, et al. WCLC 2016
